What conditions does Immatics US, Inc. run trials for?

In our tracked recruiting trials, Immatics US, Inc. sponsors trials for Melanoma, Cancer, Cutaneous Melanoma.

Clinical trials sponsored by Immatics US, Inc.

Recruiting trials

Conditions studied

Phase 1 2Phase 2 1Phase 3 1

Condition	Trials
Melanoma	3
Cancer	1
Cutaneous Melanoma	1
Melanoma, Cutaneous Malignant	1
Recurrent Cancer	1
Refractory Cancer	1
Solid Tumor, Adult	1
Synovial Sarcoma	1

ACTengine® IMA203 Combined With mRNA-4203
NCT06946225 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
NCT03686124 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 71 locations

Immatics US, Inc. is the lead sponsor of 3 recruiting trials.

No. For the full record, search ClinicalTrials.gov.